Miro1 mediates skeletal muscle insulin resistance in type 2 diabetes.
Elizabeth C Heintz, Wagner S Dantas, Analisa L Taylor et al.
✦ AI-curated · Sources linked
In 30 seconds
This study investigated whether mitochondrial Rho GTPase 1 (Miro1) contributes to skeletal muscle insulin resistance in type 2 diabetes (T2D). In a cross-sectional clinical study, Miro1 accumulation was observed in skeletal muscle from people with obesity and T2D, with similar findings in mouse models. The authors linked this accumulation to inadequate insulin-mediated AKT–Miro1 interaction. In a randomized controlled trial, exercise training reduced muscle Miro1 accumulation while improving insulin sensitivity in patients with T2D. Muscle-specific Miro1 deletion also improved oxidative capacity and insulin sensitivity in mice and cells.
Key findings
- Skeletal muscle Miro1 accumulation was observed in patients with obesity and T2D and replicated in mouse models.
- Inadequate insulin-mediated interaction between AKT and Miro1 was identified as an explanation for Miro1 accumulation.
- In a randomized controlled trial, exercise training reduced muscle Miro1 accumulation while improving insulin sensitivity in patients with T2D.
- Muscle-specific Miro1 deletion improved oxidative capacity and insulin sensitivity in mice and cells.
Why it matters
The findings connect altered mitochondrial regulation with impaired skeletal muscle insulin action in T2D and suggest Miro1 may be involved in this relationship. The clinical trial observation that exercise training coincided with lower Miro1 accumulation and improved insulin sensitivity adds human evidence to the mechanistic findings, although the abstract does not quantify the changes.
What to keep in mind
The abstract provides no sample sizes or quantitative effect estimates. The clinical observational component is cross-sectional, and the mechanistic deletion findings are from mice and cells.